(Q32118783)

English

High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

author name string

Tarella C

1

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Zallio F

2

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Caracciolo D

3

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Cuttica A

4

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Corradini P

5

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Gavarotti P

6

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Ladetto M

7

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Podio V

8

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Sargiotto A

9

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Rossi G

10

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Gianni AM

11

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Pileri A

12

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 February 2001

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

15

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

256-263

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

The place of high-dose therapy with haemopoietic stem cell transplantation in relapsed and refractory Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

High-Dose Chemotherapy and Autologous Bone Marrow Transplantation Compared with MACOP-B in Aggressive B-Cell Lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte-macrophage colony-stimulating factor to harvest circulating haemopoietic stem cells for autotransplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of the use of marrow transplantation in the treatment of non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for doxorubicin-induced congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective study of cardiomyopathy induced by adjuvant doxorubicin therapy in patients with soft-tissue sarcomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose mitoxantrone in acute leukaemia: New York Medical College experience

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose mitoxantrone with peripheral blood progenitor cell rescue: toxicity, pharmacokinetics and implications for dosage and schedule

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

G-CSF administration following peripheral blood progenitor cell (PBPC) autograft in lymphoid malignancies: evidence for clinical benefits and reduction of treatment costs

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economic benefit

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of relapse in large-cell lymphoma patients with bulk disease: implications for the use of adjuvant radiation therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Durability of hematopoiesis following autografting with peripheral blood hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcome of clinical congestive heart failure induced by anthracycline chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Relationship between cumulative anthracycline dose and late cardiotoxicity in childhood acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

High-dose carboplatin, etoposide and melphalan (CEM) with peripheral blood progenitor cell support as late intensification for high-risk cancer: non-haematological, haematological toxicities and role of growth factor administration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402011

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2402011

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q32118783&oldid=2175456891"